Table 3.

Safety outcomes

OutcomesSPS (n=16)Placebo (n=16)P Value
Nausea, no. (%)4 (25.0)2 (12.5)0.65
Vomiting, no. (%)2 (12.5)1 (6.3)>0.99
Constipation, no. (%)6 (37.5)4 (25.0)0.70
Diarrhea, no. (%)4 (25.0)8 (50.0)0.27
Electrolyte disturbances, no. (%)a
 Hypokalemia (<3.5 mEq/L)3 (18.8)00.23
 Hypernatremia (>140 mEq/L)00N/A
 Hypophosphatemia (<2.17 mg/dl)00N/A
 Hypocalcemia (<8.48 mg/dl)3 (18.8)00.23
 Hypomagnesemia (<1.4 mEq/L)5 (31.2)1 (6.3)0.17
Any adverse event, no. (%)12 (75.0)10 (58.8)0.47
  • Patients who had received at least one dose of the study drug were included in the safety analysis. One patient was lost to follow-up, and no safety data were collected. All gastrointestinal adverse events presented were specifically questioned on follow-up days 3 and 7. SPS, sodium polystyrene sulfonate; N/A, not applicable.

  • a To convert sodium levels from milliequivalents per liter to millimoles per liter, multiply by 1. To convert potassium levels from milliequivalents per liter to millimoles per liter, multiply by 1. To convert phosphorus levels from milligrams per deciliter to millimoles per liter, multiply by 0.32. To convert calcium levels from milligrams per deciliter to millimoles per liter, multiply by 0.25. To convert magnesium levels from milliequivalents per liter to millimoles per liter, multiply by 0.5.